Sandra E. Poole
Direktor/Vorstandsmitglied bei TRAVERE THERAPEUTICS, INC.
Vermögen: 126 665 $ am 30.04.2024
Profil
Sandra E.
Poole is currently the Director at ViaCyte, Inc., Independent Director at Travere Therapeutics, Inc., and Chief Operating Officer at Mythic Therapeutics, Inc. Her former positions include Managing Director at S.
Poole Consulting LLC, EVP-Technical Operations & Commercial Development at ImmunoGen, Inc., Senior Vice President-Biologics Manufacturing at Genzyme Corp., Chief Operating Officer at Candel Therapeutics, Inc., Member-Supervisory Board at Valneva SE, and Chief Operating Officer at LogicBio Therapeutics, Inc. Poole received her undergraduate and graduate degrees from The University of Waterloo.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 08.05.2024 | 23 500 ( 0,03% ) | 126 665 $ | 30.04.2024 |
Aktive Positionen von Sandra E. Poole
| Unternehmen | Position | Beginn |
|---|---|---|
| TRAVERE THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 13.05.2019 |
ViaCyte, Inc.
 ViaCyte, Inc. Pharmaceuticals: MajorHealth Technology ViaCyte, Inc. develops a stem cell-derived islet replacement therapy for the treatment of diabetes. Its development portfolio includes VC-01 product candidate, a cell replacement therapy for the treatment of type 1 diabetes. The company was founded in 1999 and is headquartered in San Diego, CA. | Direktor/Vorstandsmitglied | 27.06.2019 |
Mythic Therapeutics, Inc.
 Mythic Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mythic Therapeutics, Inc. engages in the development of cancer therapeutics. The company was founded on June 6, 2018 and is headquartered in Waltham, MA. | Geschäftsführer | 01.07.2020 |
Ehemalige bekannte Positionen von Sandra E. Poole
| Unternehmen | Position | Ende |
|---|---|---|
| VALNEVA | Direktor/Vorstandsmitglied | 17.06.2020 |
| CANDEL THERAPEUTICS, INC. | Geschäftsführer | 01.03.2020 |
| LOGICBIO THERAPEUTICS, INC. | Geschäftsführer | 31.03.2019 |
S. Poole Consulting LLC
 S. Poole Consulting LLC Miscellaneous Commercial ServicesCommercial Services S. Poole Consulting LLC provides business consulting services. The private company is based in Boston, MA. | Corporate Officer/Principal | 01.03.2018 |
| IMMUNOGEN, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2017 |
Ausbildung von Sandra E. Poole
| The University of Waterloo | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| IMMUNOGEN, INC. | Health Technology |
| VALNEVA | Health Technology |
| TRAVERE THERAPEUTICS, INC. | Health Technology |
| CANDEL THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 5 |
|---|---|
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
S. Poole Consulting LLC
S. Poole Consulting LLC Miscellaneous Commercial ServicesCommercial Services S. Poole Consulting LLC provides business consulting services. The private company is based in Boston, MA. | Commercial Services |
LogicBio Therapeutics, Inc.
 LogicBio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology LogicBio Therapeutics, Inc. engages in the development of a genome editing technology platform. It focuses on the commercialization of GeneRide, which enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination. Its pipeline includes LB-001, LB-301 and LB-401. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Lexington, MA. | Health Technology |
ViaCyte, Inc.
ViaCyte, Inc. Pharmaceuticals: MajorHealth Technology ViaCyte, Inc. develops a stem cell-derived islet replacement therapy for the treatment of diabetes. Its development portfolio includes VC-01 product candidate, a cell replacement therapy for the treatment of type 1 diabetes. The company was founded in 1999 and is headquartered in San Diego, CA. | Health Technology |
Mythic Therapeutics, Inc.
Mythic Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mythic Therapeutics, Inc. engages in the development of cancer therapeutics. The company was founded on June 6, 2018 and is headquartered in Waltham, MA. | Health Technology |
